DeepMed Research

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy of Manual Toothbrushes in Removing Dental Plaque

Not Applicable

Completed

Conditions: Dental Plaque
Oral Hygiene

Interventions: Other: Oral B Indicator 123
Other: Dr Best Original
Other: Dr Best Multi Expert
Other: parodontax Interdental

First Posted Date: 2019-07-19

Last Posted Date: 2021-01-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 80

Registration Number: NCT04025684

Locations: 🇬🇧
GSK Investigational Site, Birmingham, West Midlands, United Kingdom

A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

Phase 3

Completed

Conditions: Urinary Tract Infections

Interventions: Drug: Gepotidacin
Drug: Nitrofurantoin
Drug: Placebo matching gepotidacin
Drug: Placebo matching nitrofurantoin

First Posted Date: 2019-07-16

Last Posted Date: 2023-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1531

Registration Number: NCT04020341

Locations: 🇬🇧
GSK Investigational Site, Peterborough, United Kingdom

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

Phase 3

Completed

Conditions: Gonorrhea

Interventions: Drug: Ceftriaxone
Drug: Gepotidacin
Drug: Azithromycin

First Posted Date: 2019-07-08

Last Posted Date: 2024-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 628

Registration Number: NCT04010539

Locations: 🇬🇧
GSK Investigational Site, St Helens, United Kingdom

A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Serum
Other: Lotion
Other: Cream
Other: Normal Saline

First Posted Date: 2019-07-05

Last Posted Date: 2021-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT04006795

Locations: 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil

To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Lotion
Other: Cream
Other: Serum
Other: Normal Saline

First Posted Date: 2019-07-05

Last Posted Date: 2020-12-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 302

Registration Number: NCT04007159

Locations: 🇧🇷
GSK Investigational Site, Campinas, São Paulo, Brazil

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Phase 1

Recruiting

Conditions: Herpes Zoster

Interventions: Biological: PED-HZ/su

First Posted Date: 2019-07-05

Last Posted Date: 2025-04-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 184

Registration Number: NCT04006808

Locations: 🇬🇧
GSK Investigational Site, Southampton, United Kingdom

Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat

Phase 1

Completed

Conditions: Cholestasis

Interventions: Drug: Linerixibat tablet
Drug: [14C]-linerixibat intravenous infusion
Drug: Linerixibat oral solution

First Posted Date: 2019-06-19

Last Posted Date: 2020-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT03992014

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Tofacitinib 5 mg
Biological: GSK3196165 (Otilimab)
Drug: Placebo

First Posted Date: 2019-06-10

Last Posted Date: 2024-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1537

Registration Number: NCT03980483

Locations: 🇬🇧
GSK Investigational Site, Kenilworth, Warwickshire, United Kingdom

Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States

Completed

Conditions: Whooping Cough

Interventions: Other: Not applicable / dataset analysis

First Posted Date: 2019-06-04

Last Posted Date: 2020-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 290

Registration Number: NCT03973905

Locations: 🇧🇪
GSK Investigational Site, Wavre, Belgium

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Phase 3

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Biological: GSK3196165 (Otilimab)
Drug: Tofacitinib
Drug: Placebo

First Posted Date: 2019-06-03

Last Posted Date: 2023-11-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1764

Registration Number: NCT03970837

Locations: 🇬🇧
GSK Investigational Site, Kenilworth, Warwickshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy